Yunyi Kang

Yunyi Kang is a Principal Scientist at Calidi Biotherapeutics since April 2022, where leadership in the development of an immuno-oncology cancer vaccine platform utilizing a next-generation oncolytic virus has been highlighted, alongside contributions to regulatory documents, business development efforts, and patent applications. Prior experience includes roles as a Senior Scientist at Calibr at Scripps Research from August 2018 to April 2022, leading IND-enabling studies and collaborations for CAR-T target discovery and autoimmune disease projects. At Sanford Burnham Prebys Medical Discovery Institute, from March 2010 to August 2018, work focused on tumor-associated macrophages in acute myeloid leukemia and multiple myeloma. In addition, a Senior Scientist role at Salgomed Inc involved investigating immune inhibitory receptors through cellular network analysis. Yunyi Kang holds a Ph.D. in Cell Biology and Stem Cell Technology from Imperial College London, a Master's in Biochemical Engineering from the University of Birmingham, and a Bachelor's in Chemical Engineering from Yonsei University.